stockrow
Friday 6 November 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023.
- Revenue
- +256.1%
- EPS
- +120.0%
- Free cash flow
- +146.5%
Quarter to June 2026, against a year earlier
1.00
0.02
−1.96%
Follow HOWL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 16 | 20 | 2 | — | 24 | (66.1%) | 0 | 0 | 0 | 0.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | — | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (10) | (15) | (50) | (54) | (37) | (71) | (61) | (35) | +34.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (328.09) | (187.37) | (3,740.85) | 0.00 | (141.94) | 0.0 pt | ||||||
| Net income | — | 0 | — | (10) | (15) | (50) | (54) | (37) | (71) | (61) | (35) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.57 | 0.56 | 0.04 | 0.00 | 0.50 | n/m | |||||
| Earnings | — | — | — | (28.49) | (28.08) | (10.94) | (1.86) | (1.05) | (1.63) | (1.32) | (0.73) | (40.1%) | ||||||
| Cash flow | — | — | — | (14.91) | (18.53) | (2.32) | (1.41) | (0.91) | (1.30) | (1.31) | (0.62) | (33.3%) | ||||||
| Capex | — | — | — | (0.42) | (0.56) | (0.03) | (0.13) | (0.02) | (0.01) | 0.00 | 0.01 | n/m | ||||||
| Free cash flow | — | — | — | (15.32) | (19.09) | (2.35) | (1.53) | (0.94) | (1.30) | (1.31) | (0.61) | (33.6%) | ||||||
| Book value | — | — | — | (37.97) | (51.60) | 8.28 | 4.24 | 3.12 | 1.69 | 0.54 | 0.34 | n/m | ||||||
| Shares, m | — | — | — | 1 | 1 | 18 | 29 | 36 | 43 | 46 | 47 | +103.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 8.29 | 6.91 | — | 1.99 | 5.1 | ||||||
| P/B | — | — | — | — | — | — | 0.48 | 1.49 | 0.87 | — | 2.98 | 0.9 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 3.19 | (2.24) | — | 1.98 | 0.3 | ||||||
| EV/FCF | — | — | — | — | — | — | 1.30 | (1.91) | 0.37 | — | (1.62) | (0.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (10) | (19) | (43) | (41) | (33) | (56) | (60) | (30) | +36.0% | |||||
| Capex | — | — | — | 0 | (1) | 0 | (4) | (1) | 0 | — | 0 | (0.9%) | ||||||
| Free cash flow | — | — | — | (10) | (19) | (43) | (44) | (33) | (56) | (60) | (30) | +35.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 16 | 88 | 149 | 116 | 119 | 98 | 22 | 15 | +5.8% | |||||
| Net debt | — | — | — | (8) | (91) | (143) | (117) | (102) | (85) | (57) | (22) | +38.6% | ||||||
| Shareholders’ equity | — | — | — | (24) | (52) | 153 | 122 | 111 | 73 | 25 | 16 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (168.17) | (47.79) | (146.51) | (31.70) | (22.30) | (46.74) | (61.96) | (59.31) | +106.2 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (317.97) | (623.18) | (261.32) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 47.87 | 74.09 | (400.15) | (39.12) | (31.98) | (76.33) | (123.88) | (119.86) | (171.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 24 | 39 | 46 | 47 | 46 | 39 | — | +10.2% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.36 | 0.42 | 0.04 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Werewolf Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $50.5M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $49.6M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | |
| APLM Apollomics Inc. | $49.5M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| TIL Instil Bio, Inc. | $47.4M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $47.3M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $50.9M | — | — | — | — | +17.84% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2025
Ownership
Directors and executive officers, together
23.60%
Entities affiliated with RA Capital
13.80%
Luke Evnin, Ph.D.
9.80%
Entities affiliated with MPM Capital
9.60%
PFM Health Sciences, LP
6.50%
UBS Oncology Impact Fund, L.P.
5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement